Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focusing on novel therapies for metabolic and endocrine disorders, has announced its plans to release financial results for the second quarter of 2024 after market close on July 24, 2024. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the financial results and provide general corporate updates.
Interested parties can participate in the conference call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. A telephone replay will be available until July 31, 2024. The call can also be accessed via webcast on Viking's website, with an archive available for 30 days.
- None.
- None.
Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time
The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 24, 2024. To participate on the conference call, please dial (844) 850-0543 from the
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. Viking is also developing VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. The company is also evaluating an oral formulation of VK2735 in a Phase 1 trial. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-second-quarter-2024-on-july-24-2024-302198963.html
SOURCE Viking Therapeutics, Inc.
FAQ
When will Viking Therapeutics (VKTX) report its Q2 2024 financial results?
What time is Viking Therapeutics' (VKTX) Q2 2024 earnings conference call?
How can investors access Viking Therapeutics' (VKTX) Q2 2024 earnings call?
Until what date will the replay of Viking Therapeutics' (VKTX) Q2 2024 earnings call be available?
